Yi-ming Sun - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Yi-ming Sun

Showing results (71-80 of 73) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 73 results.

EMBO Molecular Medicine|January 18, 2023

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceLi-Min Wang, Pingyuan Wang, Xiao-Min Chen, et al.

Cancer Letters|November 17, 2016

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trialsBo Yuan, Na Ye, Shan-Shan Song, et al.

Oncotarget|December 8, 2016

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distributionJin-Xue He, Meng Wang, Xia-Juan Huan, et al.

Pageof 8

Search research articles

Showing results (71-80 of 73) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 73 results.

EMBO Molecular Medicine|January 18, 2023

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceLi-Min Wang, Pingyuan Wang, Xiao-Min Chen, et al.

Cancer Letters|November 17, 2016

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trialsBo Yuan, Na Ye, Shan-Shan Song, et al.

Oncotarget|December 8, 2016

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distributionJin-Xue He, Meng Wang, Xia-Juan Huan, et al.

Pageof 8